Zusammenfassung
Die Riesenzellarteriitis (RZA) ist die in der Gefäßmedizin bedeutsamste systemische Vaskulitis. Fortschritte in der bildgebenden Diagnostik, unter anderem der Sonographie, haben die Diagnosestellung der RZA in den letzten 2 Jahrzehnten dramatisch verbessert. Mit dem Interleukin-6-Rezeptor-Antagonisten Tocilizumab steht das erste spezifisch für die RZA zugelassene Medikament zur Verfügung. Angesichts häufiger kranialer und extrakranialer ischämischer Frühkomplikationen und dem bei dieser Erkrankung deutlich erhöhten Risiko für aortale Spätkomplikationen (insb. Aneurysma und Dissektion der thorakalen Aorta) ist der vaskuläre Mediziner heutzutage gefragt wie nie zuvor im interdisziplinären Management dieser Erkrankung.
Abstract
Giant cell arteritis (GCA) is the most important form of systemic vasculitis in Vascular Medicine. Major advances in diagnostic imaging including sonography have significantly improved the diagnosis of GCA in the past two decades. Nonetheless, temporal artery biopsy still plays a role in the diagnostic work-up of suspected GCA. The interleukin-6 receptor antagonist tocilizumab is the first promising treatment option for GCA since the introduction of corticosteroids. Early ischemic complications not only affect the eyes but also frequently the extremities and there is a substantial risk of late thoracic aortic complications (e.g. aneurysm and dissection). Given the advances in the understanding of this systemic vascular disease, the vascular medical specialist nowadays plays an important role in the interdisciplinary management of GCA.
Literatur
Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therneau TM, Gabriel SE (2011) The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 63(3):633–639
Weyand CM, Goronzy JJ (2013) Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 9(12):731–740
Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM (2010) Th17 and Th1 T‑cell responses in giant cell arteritis. Circulation 121(7):906–915
Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM (2008) Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118(12):1276–1284
Soriano A, Muratore F, Pipitone N, Boiardi L, Cimino L, Salvarani C (2017) Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol 13(8):476–484
Prieto-González S, Arguis P, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Butjosa M, Sánchez M, Hernández-Rodríguez J, Grau JM, Cid MC (2012) Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 71(7):1170–1176
Czihal M, Tatò F, Rademacher A, Kuhlencordt P, Schulze-Koops H, Hoffmann (2012) Involvement of the femoropopliteal arteries in giant cell arteritis: clinical and color duplex sonography. J Rheumatol 39(2):314–321
Czihal M, Zanker S, Rademacher A, Tatò F, Kuhlencordt PJ, Schulze-Koops H, Hoffmann U (2012) Sonographic and clinical pattern of extracranial and cranial giant cell arteritis. Scand J Rheumatol 41(3):231–236
Czihal M, Tatò F, Förster S, Rademacher A, Schulze-Koops H, Hoffmann U (2010) Fever of unknown origin as initial manifestation of large vessel giant cell arteritis: diagnosis by colour-coded sonography and 18-FDG-PET. Clin Exp Rheumatol 28(4):549–552
Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, Pego-Reigosa R, Lopez-Diaz MJ, Vazquez-Triñanes MC, Miranda-Filloy JA, Blanco R, Dierssen T, Gonzalez-Juanatey C, Llorca J (2009) Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 88(4):227–235
Kuo CH, McCluskey P, Fraser CL (2016) Chewing gum test for jaw claudication in giant-cell Arteritis. N Engl J Med 374(18):1794–1795
Czihal M, Brendel T, Seibold C, Reincke M, Hoffmann U (2011) Listen to the axillary artery: diagnosis of occult giant cell arteritis. J Clin Rheumatol 17(4):214–215
Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W, Eggenberger E, Antonio-Santos A, Golnik K, Kardon R, Wall M (2006) Prevalence of a normal C‑reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 113(10):1842–1845
Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, Brouwer E, Cimmino MA, Clark E, Dasgupta B, Diamantopoulos AP, Direskeneli H, Iagnocco A, Klink T, Neill L, Ponte C, Salvarani C, Slart RHJA, Whitlock M, Schmidt WA (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77(5):636–643
Czihal M, Lottspeich C, Hoffmann U (2017) Ultrasound imaging in the diagnosis of large vessel vasculitis. Vasa 46(4):241–253
Aschwanden M, Daikeler T, Kesten F, Baldi T, Benz D, Tyndall A, Imfeld S, Staub D, Hess C, Jaeger KA (2013) Temporal artery compression sign—a novel ultrasound finding for the diagnosis of giant cell arteritis. Ultraschall Med 34(1):47–50
Schäfer VS, Juche A, Ramiro S, Krause A, Schmidt WA (2017) Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology (Oxf) 56(9):1632
Czihal M, Schröttle A, Baustel K, Lottspeich C, Dechant C, Treitl KM, Treitl M, Schulze-Koops H, Hoffmann U (2017) B‑mode sonography wall thickness assessment of the temporal and axillary arteries for the diagnosis of giant cell arteritis: a cohort study. Clin Exp Rheumatol 103(1):128–133 (35 Suppl)
Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxf) 55(1):66–70
Muratore F, Boiardi L, Restuccia G, Macchioni P, Pazzola G, Nicolini A, Germanò G, Possemato N, Cavazza A, Cavuto S, Cimino L, Pipitone N, Catanoso M, Addimanda O, Salvarani C (2013) Comparison between colour duplex sonography findings and different histological patterns of temporal artery. Rheumatology (Oxf) 52(12):2268–2274
Wilson JC, Sarsour K, Collinson N, Tuckwell K, Musselman D, Klearman M, Napalkov P, Jick SS, Stone JH, Meier CR (2017) Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum 46(6):819–827
Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, Merkel PA (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797
Samson M, Espígol-Frigolé G, Terrades-García N, Prieto-González S, Corbera-Bellalta M, Alba-Rovira R, Hernández-Rodríguez J, Audia S, Bonnotte B, Cid MC (2018) Biological treatments in giant cell arteritis & Takayasu arteritis. Eur J Intern Med 50:12–19
Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Bütikofer L, Seitz M, Reichenbach S (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387(10031):1921–1927
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N (2017) Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 377(4):317–328
Czihal M, Piller A, Schroettle A, Kuhlencordt PJ, Schulze-Koops H, Hoffmann U (2013) Outcome of giant cell arteritis of the arm arteries managed with medical treatment alone: cross-sectional follow-up study. Rheumatology (Oxf) 52(2):282–286
Both M, Aries PM, Müller-Hülsbeck S, Jahnke T, Schäfer PJ, Gross WL, Heller M, Reuter M (2006) Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. Ann Rheum Dis 65(9):1124–1130
Quinn KA, Ahlman MA, Malayeri AA, Marko J, Civelek AC, Rosenblum JS, Bagheri AA, Merkel PA, Novakovich E, Grayson PC (2018) Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis 77(8):1165–1171
Mackie SL, Hensor EM, Morgan AW, Pease CT (2014) Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis 73(1):143–148
Kebed DT, Bois JP, Connolly HM, Scott CG, Bowen JM, Warrington KJ, Makol A, Greason KL, Schaff HV, Anavekar NS (2018) Spectrum of Aortic Disease in the Giant Cell Arteritis Population. Am J Cardiol 121(4):501–508
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Czihal gibt an, Vortragshonorare von der Fa. Roche erhalten zu haben. U. Hoffmann gibt, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Czihal, M., Hoffmann, U. Riesenzellarteriitis. Gefässchirurgie 24, 128–134 (2019). https://doi.org/10.1007/s00772-019-0503-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00772-019-0503-3